Markus Warmuth, the CEO and president of Cambridge-based H3 Biomedicine, acknowledged in a recent interview that the company has remained pretty quiet since it was founded in 2011. But he says that’s about to change.
Freed from the need to raise money thanks to a 10-year, $200 million commitment from its Japanese parent company, Eisai Pharmaceuticals, H3 has toiled away on its pre-clinical cancer drugs out of public view for the past few years, he said.
Help employers find you! Check out all the jobs and post your resume.
